Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome.

Babinets LS, Melnyk NA, Shevchenko NO, Sasyk GM, Zemlyak OS, Kopach OY, Fedoriv OY.

Wiad Lek. 2018;71(2 pt 1):337-340.

PMID:
29729169
2.

Improvement of the complex medical treatment for the patients wіth chronic biliary pancreatitis.

Babinets LS, Kytsai KY, Kotsaba YY, Halabitska IM, Melnyk NA, Semenova IV, Zemlyak OS.

Wiad Lek. 2017;70(2):213-216.

PMID:
28511162
3.

Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.

Harrison JS, Frazier SR, McConnell DD, Yasar SJ, Melnyk N, Salaru G.

Blood Coagul Fibrinolysis. 2017 Jun;28(4):342-347. doi: 10.1097/MBC.0000000000000600.

PMID:
27676646
4.

Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva.

Xing D, Bakhsh S, Melnyk N, Isacson C, Ho J, Huntsman DG, Gilks CB, Ronnett BM, Horlings HM.

Int J Gynecol Pathol. 2017 May;36(3):289-293. doi: 10.1097/PGP.0000000000000324.

PMID:
27662035
5.

Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.

McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Côté A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP.

Nat Genet. 2016 Jul;48(7):758-67. doi: 10.1038/ng.3573. Epub 2016 May 16.

PMID:
27182968
6.

A clinically applicable molecular-based classification for endometrial cancers.

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Br J Cancer. 2015 Jul 14;113(2):299-310. doi: 10.1038/bjc.2015.190. Epub 2015 Jun 30.

7.

Molecular characterization of a population-based series of endometrial stromal sarcomas in Kuwait.

Ali RH, Al-Safi R, Al-Waheeb S, John B, Al-Ali W, Al-Jassar W, Al-Mulla F, Melnyk N, Huntsman DG, Lee CH.

Hum Pathol. 2014 Dec;45(12):2453-62. doi: 10.1016/j.humpath.2014.08.012. Epub 2014 Sep 4.

PMID:
25288234
8.

TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data.

Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP.

Genome Res. 2014 Nov;24(11):1881-93. doi: 10.1101/gr.180281.114. Epub 2014 Jul 24.

9.

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 27;8(9). doi: 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a. eCollection 2013.

10.

Type-specific cell line models for type-specific ovarian cancer research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4. PLoS One. 2013;8(9). doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a.

11.

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.

Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP.

J Pathol. 2013 Sep;231(1):21-34. doi: 10.1002/path.4230.

12.

Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.

McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG.

Mod Pathol. 2014 Jan;27(1):128-34. doi: 10.1038/modpathol.2013.107. Epub 2013 Jun 14.

13.

Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors.

Jakate K, Azimi F, Ali RH, Lee CH, Clarke BA, Rasty G, Shaw PA, Melnyk N, Huntsman DG, Laframboise S, Rouzbahman M.

Mod Pathol. 2013 Jan;26(1):95-105. doi: 10.1038/modpathol.2012.136. Epub 2012 Aug 24.

14.

Copy number aberrations in benign serous ovarian tumors: a case for reclassification?

Hunter SM, Anglesio MS, Sharma R, Gilks CB, Melnyk N, Chiew YE, deFazio A; Australian Ovarian Cancer Study Group, Longacre TA, Huntsman DG, Gorringe KL, Campbell IG.

Clin Cancer Res. 2011 Dec 1;17(23):7273-82. doi: 10.1158/1078-0432.CCR-11-2080. Epub 2011 Oct 5.

15.

Frequency of known gene rearrangements in endometrial stromal tumors.

Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E.

Am J Surg Pathol. 2011 Sep;35(9):1364-72. doi: 10.1097/PAS.0b013e3182262743.

PMID:
21836477
16.

deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.

McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J, Melnyk N, Pacheco M, Marra MA, Hirst M, Nielsen TO, Sahinalp SC, Huntsman D, Shah SP.

PLoS Comput Biol. 2011 May;7(5):e1001138. doi: 10.1371/journal.pcbi.1001138. Epub 2011 May 19.

17.

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD.

PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064.

18.

ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.

Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH.

Cancer Res. 2011 Feb 1;71(3):1060-70. doi: 10.1158/0008-5472.CAN-10-3096. Epub 2010 Dec 9.

19.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.

N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.

20.

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.

Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T, Chuah E, Corbett R, Fejes AP, Griffith M, Yee J, Martin M, Mayo M, Melnyk N, Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliffe M, Tam A, Terry J, Thiessen N, Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG, Birol I, Hirst M, Holt RA, Marra MA.

Genome Biol. 2010;11(8):R82. doi: 10.1186/gb-2010-11-8-r82. Epub 2010 Aug 9.

21.

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.

Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD.

Oncogene. 2010 Sep 2;29(35):4905-13. doi: 10.1038/onc.2010.245. Epub 2010 Jun 28.

22.

The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.

Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG.

PLoS One. 2009 Nov 24;4(11):e7988. doi: 10.1371/journal.pone.0007988.

23.

Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition.

Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH.

Cancer Cell. 2009 May 5;15(5):402-15. doi: 10.1016/j.ccr.2009.03.017.

24.

The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.

Zhang L, Anglesio MS, O'Sullivan M, Zhang F, Yang G, Sarao R, Mai PN, Cronin S, Hara H, Melnyk N, Li L, Wada T, Liu PP, Farrar J, Arceci RJ, Sorensen PH, Penninger JM.

Nat Med. 2007 Sep;13(9):1060-9. Epub 2007 Aug 12.

PMID:
17694067
25.

The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

Martin MJ, Melnyk N, Pollard M, Bowden M, Leong H, Podor TJ, Gleave M, Sorensen PH.

Mol Cell Biol. 2006 Mar;26(5):1754-69.

26.

Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney.

Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, Grundy PE, Leach S, Marra MA, Brooks-Wilson AR, Penninger J, Sorensen PH.

Hum Mol Genet. 2004 Sep 15;13(18):2061-74. Epub 2004 Jul 14.

PMID:
15254018
27.

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH.

Cancer Cell. 2002 Nov;2(5):367-76.

28.

Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.

Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, Sorensen PH.

Cancer Res. 2002 Aug 15;62(16):4704-10.

Supplemental Content

Loading ...
Support Center